Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world.

Employee Rating

2.5More
TypePublic
HQConcord, US
Founded1991
Size (employees)204 (est)
Websitecerus.com
Cerus was founded in 1991 and is headquartered in Concord, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Cerus

William M. Greenman

William M. Greenman

President and CEO
Kevin D. Green

Kevin D. Green

VP, Finance & CFO
Laurence M. Corash

Laurence M. Corash

Svp, CMO & CSO
Show more

Cerus Office Locations

Cerus has offices in Concord and Amersfoort
Concord, (HQ)
2550 Stanwell Dr
Amersfoort,
79 Stationsstraat
Show all (2)
Report incorrect company information

Cerus Financials and Metrics

Cerus Revenue

Cerus 's revenue was reported to be $39.28 m in FY, 2016 which is a 14.8% increase from the previous period.
USD

Revenue (Q3, 2018)

15.4m

Gross profit (Q3, 2018)

7.3m

Gross profit margin (Q3, 2018), %

47.1%

Net income (Q3, 2018)

(14.2m)

EBIT (Q3, 2018)

(13.6m)

Market capitalization (12-Dec-2018)

780.2m

Closing stock price (12-Dec-2018)

5.8

Cash (30-Sep-2018)

22.3m
Cerus 's current market capitalization is $780.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

39.7m36.4m34.2m39.3m

Revenue growth, %

(8%)(6%)15%

Cost of goods sold

21.2m23.5m

Gross profit

15.2m10.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

8.6m10.4m7.7m8.8m8.0m7.6m9.3m15.4m15.4m

Cost of goods sold

4.8m5.7m4.7m7.0m5.6m4.3m5.0m7.7m8.1m

Gross profit

3.8m4.7m3.0m1.8m2.5m3.4m4.3m7.7m7.3m

Gross profit Margin, %

45%45%39%20%31%44%46%50%47%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

29.5m22.8m71.0m22.6m13.7m

Accounts Receivable

6.1m5.5m5.8m6.9m12.4m

Inventories

13.1m15.0m10.8m12.5m14.5m

Current Assets

78.2m74.9m130.4m94.1m89.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

24.4m24.0m28.6m22.3m17.9m35.1m50.8m20.8m7.7m12.9m10.9m20.3m17.0m14.9m14.3m22.3m

Accounts Receivable

7.0m4.9m4.5m7.4m5.2m5.4m5.6m4.1m5.1m7.4m5.6m7.9m10.5m10.5m11.4m10.5m

Inventories

12.7m11.3m13.4m13.5m16.1m13.7m12.8m11.3m12.1m12.2m12.9m12.2m14.3m13.2m12.9m13.3m

Current Assets

74.5m67.1m70.3m72.7m136.4m144.5m128.4m119.4m112.2m108.0m75.7m74.3m88.4m133.8m141.2m150.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(43.3m)(38.8m)(55.9m)(62.9m)(60.6m)

Depreciation and Amortization

557.0k202.0k1.7m1.8m1.8m

Inventories

(1.8m)3.0m4.0m(1.8m)(2.1m)

Accounts Payable

(1.5m)(973.0k)(3.9m)3.3m2.5m
USDY, 2018

Financial Leverage

1.8 x
Show all financial metrics

Cerus Operating Metrics

FY, 2016

Patents Issued

93
Show all operating metrics
Report incorrect company information

Cerus Online and Social Media Presence

Embed Graph
Report incorrect company information

Cerus News and Updates

Cerus Endovascular Expands Intellectual Property Portfolio

FREMONT, Calif. and OXFORD, England, Nov. 27, 2018 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiological devices and delivery systems to treat acute,...

Cerus Endovascular Enrolls First Patients in CERUS Study to Treat Intra-Cranial Aneurysms Using Contour Neurovascular System™ to Reduce the Risk of Rupture

FREMONT, Calif. and OXFORD, United Kingdom, Nov. 13, 2018 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held medical device company engaged in developing interventional neuroradiology devices and delivery systems to treat acute, life-threatening intracranial aneurysms, today...

Cerus Endovascular Strengthens Board of Directors with Appointment of John T. Kilcoyne

FREMONT, Calif. and OXFORD, England, Sept. 18, 2018 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems...

Zika Virus 2018 Global Market Key Players – Intrexon, Cerus, Sanofi, NewLink Genetics, Immunovaccine, GlaxoSmithKline– Analysis and Forecast to 2025

WiseGuyRerports.com Presents “Global Zika Virus Market Research Report 2018” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Cerus Company Life and Culture

Report incorrect company information

Cerus Frequently Asked Questions

  • When was Cerus founded?

    Cerus was founded in 1991.

  • Who are Cerus key executives?

    Cerus 's key executives are William M. Greenman, Kevin D. Green and Laurence M. Corash.

  • How many employees does Cerus have?

    Cerus has 204 employees.

  • Who are Cerus competitors?

    Competitors of Cerus include Motus GI, Zenflow and Becton Dickinson.

  • Where is Cerus headquarters?

    Cerus headquarters is located at 2550 Stanwell Dr, Concord.

  • Where are Cerus offices?

    Cerus has offices in Concord and Amersfoort.

  • How many offices does Cerus have?

    Cerus has 2 offices.